NewsBenzingaIDEAYA Biosciences: BPA del tercer trimestre de $(1,22) no alcanza la estimación de $(1,18); ventas de $10,242 millones superan la estimación de $6,857 millones IDEAYA Biosciences: BPA del tercer trimestre de $(1,22) no alcanza la estimación de $(1,18); ventas de $10,242 millones superan la estimación de $6,857 millones Benzinga 2026.11.03 11:15 (GMT+0) Open on Benzinga Other news Jim Cramer Likes This Industrial Stock: ‘It’s Come Down A Great Deal’ These Analysts Revise Their Forecasts On Palantir After Q3 Results Xiaomi Discloses 8-Hour Humanoid Robot Factory Work and Long-Horizon Home Task Progress Needham Reiterates Buy on ON Semiconductor, Maintains $116 Price Target Zebra Technologies Narrows FY2026 Adj EPS Guidance from $20.75-$21.25 to $21.20 vs $20.89 Est; Raises FY2026 Sales Guidance from $6.151B-$6.259B to $6.313B vs $6.212B Est Hydrofarm Eliminates $109M Term Loan After Recapitalization
Zebra Technologies Narrows FY2026 Adj EPS Guidance from $20.75-$21.25 to $21.20 vs $20.89 Est; Raises FY2026 Sales Guidance from $6.151B-$6.259B to $6.313B vs $6.212B Est
